TrxR1 is also a validated cancer target, and several efforts are underway to generate new inhibitors of TrxR1 that can compromise the rapid growth of cancer cells (Arnér, 2017; Hasan et al., 2022). This evidence concerns the gene TXNRD1 and cancer.